Microbiome-focused drug development is often thought of as the addition of beneficial strains or consortia of bacteria to specific sites in the body. Yet some drug products rather aim to take away elements or profoundly […]
EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, today announces it has raised more than €5 million (approx. $6M) in a Series A funding from […]
SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate […]
ADM (NYSE: ADM), a global leader in nutrition and agricultural origination and processing, announced a significant expansion of its broad portfolio of health and wellness products and solutions with an agreement to purchase U.S.-based Deerland […]
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25 million Series C financing. OneVentures, a venture capital firm headquartered in Sydney, […]
Nascent, Complex, and Evolving Market The microbial population in the human body the human microbiome numbers in the trillions,(1) and genes within these microbes are often referred to as the “second genome”(2). Most commensal, symbiotic, […]
The University of Texas MD Anderson Cancer Center and SNIPR BIOME announced a strategic collaboration to advance new CRISPR-based microbiome therapeutics to reduce immune-related adverse events (irAE) in patients being treated with combined immune checkpoint inhibitors. […]
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) […]
DayTwo, a leader in precision nutrition with the world’s most advanced proprietary microbiome science, today announced that the company appointed David Henderson, a former founding executive member of Oscar Health, as Chief Executive Officer. The […]
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The […]